Literature DB >> 12433837

Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs.

Mitsuho Onimaru1, Yoshikazu Yonemitsu, Mitsugu Tanii, Kazunori Nakagawa, Ichiro Masaki, Shinji Okano, Hiroaki Ishibashi, Kanemitsu Shirasuna, Mamoru Hasegawa, Katsuo Sueishi.   

Abstract

Hepatocyte growth factor (HGF) is a potent angiogenic polypeptide that stimulates angiogenesis. Transcriptional regulation of HGF, however, has not been fully defined, with the exception of the hypoxia-mediated downregulation in cultured cells. In the present study, we report that angiogenic growth factors, including HGF, were upregulated in a murine model of critical limb ischemia in vivo, a finding that was in conflict with previous in vitro data. Mice deficient in basic fibroblast growth factor-2 (FGF-2) showed reduced induction of HGF protein in ischemic muscles, and overexpression of FGF-2 via gene transfer stimulated endogenous HGF, irrespective of the presence of ischemia. In culture, FGF-2 rapidly stimulated HGF mRNA, and a sustained expression was evident in the time course in vascular smooth muscle cells and fibroblasts. FGF-2-mediated induction of HGF was fully dependent on the mitogen-activated protein kinase pathway yet was not affected by either hypoxia or a protein kinase A inhibitor. In the early expression, FGF-2 directly stimulated HGF mRNA without the requirement of new protein synthesis, whereas sustained induction of HGF in the later phase was partly mediated by platelet-derived growth factor-AA. Furthermore, in vivo overexpression of FGF-2 significantly improved the blood perfusion, and the effect was abolished by systemic blockade of HGF in ischemic limbs. This is the first demonstration of a regulational mechanism of HGF expression via FGF-2 that was independent of the presence of hypoxia. The harmonized therapeutic effects of FGF-2, accompanied with the activity of endogenous HGF, may provide a beneficial effect for the treatment of limb ischemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433837     DOI: 10.1161/01.res.0000043281.66969.32

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  20 in total

1.  FGF-dependent regulation of VEGF receptor 2 expression in mice.

Authors:  Masahiro Murakami; Loc T Nguyen; Kunihiko Hatanaka; William Schachterle; Pei-Yu Chen; Zhen W Zhuang; Brian L Black; Michael Simons
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production.

Authors:  Monika Litwin; Agata Radwańska; Maria Paprocka; Claudine Kieda; Tadeusz Dobosz; Wojciech Witkiewicz; Dagmara Baczyńska
Journal:  Mol Cell Biochem       Date:  2015-08-28       Impact factor: 3.396

Review 3.  Fibroblast growth factor regulation of neovascularization.

Authors:  Masahiro Murakami; Michael Simons
Journal:  Curr Opin Hematol       Date:  2008-05       Impact factor: 3.284

4.  Micro- and Nanoparticles for Treating Cardiovascular Disease.

Authors:  S Suarez; A Almutairi; K L Christman
Journal:  Biomater Sci       Date:  2015-04       Impact factor: 6.843

5.  Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation.

Authors:  B Ferraro; Y L Cruz; M Baldwin; D Coppola; R Heller
Journal:  Gene Ther       Date:  2010-04-15       Impact factor: 5.250

6.  Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2.

Authors:  Takaaki Fujii; Hiroyuki Kuwano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-01-29       Impact factor: 2.416

7.  Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration.

Authors:  Ji Hyung Chung; Eun Kyoung Im; Tae Won Jin; Seung-Min Lee; Soo Hyuk Kim; Eun Young Choi; Min-Jeong Shin; Kyung Hye Lee; Yangsoo Jang
Journal:  Exp Mol Med       Date:  2011-04-30       Impact factor: 8.718

8.  Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.

Authors:  Masaki Matsuura; Mitsuho Onimaru; Yoshikazu Yonemitsu; Hanako Suzuki; Toshiaki Nakano; Hiroaki Ishibashi; Kanemitsu Shirasuna; Katsuo Sueishi
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

9.  DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial.

Authors:  Yoshikazu Yonemitsu; Takuya Matsumoto; Hiroyuki Itoh; Jin Okazaki; Makiko Uchiyama; Kumi Yoshida; Mitsuho Onimaru; Toshihiro Onohara; Hiroyuki Inoguchi; Ryoichi Kyuragi; Mototsugu Shimokawa; Hiroshi Ban; Michiko Tanaka; Makoto Inoue; Tsugumine Shu; Mamoru Hasegawa; Yoichi Nakanishi; Yoshihiko Maehara
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

10.  Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression.

Authors:  Dhruv Kumar; Jacob New; Vikalp Vishwakarma; Radhika Joshi; Jonathan Enders; Fangchen Lin; Sumana Dasari; Wade R Gutierrez; George Leef; Sivapriya Ponnurangam; Hemantkumar Chavan; Lydia Ganaden; Mackenzie M Thornton; Hongying Dai; Ossama Tawfik; Jeffrey Straub; Yelizaveta Shnayder; Kiran Kakarala; Terance Ted Tsue; Douglas A Girod; Bennett Van Houten; Shrikant Anant; Partha Krishnamurthy; Sufi Mary Thomas
Journal:  Cancer Res       Date:  2018-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.